Expression pattern of the thioredoxin system in human endothelial progenitor cells and endothelial cells under hypoxic injury.
OBJECTIVE
The thioredoxin (TRx) system is a ubiquitous thiol oxidoreductase pathway that regulates cellular reduction/oxidation status. Although endothelial cell (EC) hypoxic damage is one of the important pathophysiologic mechanisms of ischemic heart disease, its relationship to the temporal expression pattern of the TRx system has not yet been elucidated well. The work presented here was performed to define the expression pattern of the TRx system and its correlation with cellular apoptosis in EC lines in hypoxic stress. These results should provide basic clues for applying aspects of the TRx system as a therapeutic molecule in cardiovascular diseases.


METHODS
Hypoxia was induced with 1% O(2), generated in a BBL GasPak Pouch (Becton Dickinson, Franklin Lakes, NJ, USA) in human endothelial progenitor cells (hEPC) and human umbilical vein endothelial cells (HUVEC). Apoptosis of these cells was confirmed by Annexin-V: Phycoerythrin flow cytometry. Expression patterns of TRx; TRx reductase; TRx interacting protein; and survival signals, such as Bcl-2 and Bax, in ECs under hypoxia were checked.


RESULTS
Apoptosis was evident after hypoxia in the two cell types. Higher TRx expression was observed at 12 hours after hypoxia in hEPCs and 12, 36, 72 hours of hypoxia in HUVECs. The expression patterns of the TRx system components showed correlation with EC apoptosis and cell survival markers.


CONCLUSIONS
Hypoxia induced significant apoptosis and its related active changes of the TRx system were evident in human EC lines. If the cellular impact of TRx expression pattern in various cardiovascular tissues under hypoxia or oxidative stress was studied meticulously, the TRx system could be applied as a new therapeutic target in cardiovascular diseases, such as ischemic heart disease or atherosclerosis.
Division of Cardiology, Department of Internal Medicine, Chungbuk National University School of Medicine, Cheongju, Korea.
Keon-Jae
KJ
Park
Yeon-Jeong
YJ
Kim
Eun Ju
EJ
Choi
No Kwan
NK
Park
Gi Hyun
GH
Kim
Sang Min
SM
Kim
Sang Yeub
SY
Lee
Jang-Whan
JW
Bae
Kyung-Kuk
KK
Hwang
Dong-Woon
DW
Kim
Myeong-Chan
MC
Cho
N Engl J Med. 1990 Jul 5;323(1):27-36
2113184
Science. 1997 Feb 14;275(5302):964-7
9020076
Clin Sci (Lond). 2005 May;108(5):413-24
15831090
Hum Cell. 2000 Dec;13(4):153-60
11329932
Circ Res. 2008 Nov 7;103(10):1072-83
18988904
Circulation. 2003 Oct 21;108(16):1912-6
14568884
Anal Biochem. 1982 Aug;124(2):396-405
7149237
Antioxid Redox Signal. 2003 Dec;5(6):795-802
14588153
Circulation. 2001 Nov 27;104(22):2673-8
11723017
Nat Clin Pract Endocrinol Metab. 2007 Oct;3(10):713-20
17893690
Circ Res. 2004 Jan 9;94(1):37-45
14656924
J Mol Med (Berl). 2006 Dec;84(12):997-1003
17021908
J Vasc Res. 2000 Nov-Dec;37(6):540-7
11146408
Pharmacol Ther. 1995;68(1):149-73
8604436
Circulation. 2002 Mar 26;105(12):1429-35
11914250
Mol Cell Biol. 2003 Feb;23(3):916-22
12529397
Circulation. 2004 Jun 1;109(21):2581-6
15123525
Ann N Y Acad Sci. 2005 Dec;1066:136-51
16533924
J Biol Chem. 1999 Jul 30;274(31):21645-50
10419473
Circ Res. 1999 Aug 20;85(4):357-63
10455064
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3422-7
10725398
Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1483-7
11557676
J Am Coll Cardiol. 2007 Dec 4;50(23):2249-53
18061074
Annu Rev Pharmacol Toxicol. 2001;41:261-95
11264458
Eur J Biochem. 2000 Oct;267(20):6118-25
11012663
J Biol Chem. 1998 Mar 13;273(11):6297-302
9497357
Circulation. 2004 Aug 17;110(7):856-61
15289372
FEBS Lett. 2004 Nov 19;577(3):427-33
15556622